HeartFlow Stock
HeartFlow is a medical technology company revolutionizing the diagnosis and management of coronary artery disease. Their non-invasive HeartFlow Analysis utilizes advanced imaging and artificial intelligence to provide detailed 3D models of patients' coronary arteries, enabling precise treatment planning and improving patient outcomes.
Founded: 2010
HeartFlow Company Overview
Management Team
| Dana G. Mead, Jr. President and CEO |
| Campbell Rogers, M.D., F.A.C.C. EVP and Chief Medical Officer |
| Charles A. Taylor, Ph.D. Founder and CTO |
| Lance Scott Chief Commercial Officer |
| Noemi C. Espinosa, J.D. General Counsel and Chief Ethics and Compliance Officer |
| Renata Naoumov VP and Chief People Officer |
| Christopher K. Zarins, M.D. Founder and SVP of Medical Affairs |
| Heather A. Brown, Ph.D. SVP of Market Access and Reimbursement |
| Windi Hary, RAC SVP of Clinical, Quality, and Regulatory |
| Auston Davis VP and Chief Information Security Officer |
Funding Information
News
News
New HeartFlow RoadMap Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings
April 18, 2023 — HeartFlow, Inc. announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries. With its expanded product portfolio, HeartFlow is now the only company to offer anatomical and physiological visualization of the coronary arteries to help improve heart disease diagnosis and enable physicians to guide treatment decisions. Heart disease is the leading cause of death in the United States.1 Despite advancements in the diagnosis and treatment of coronary artery disease (CAD), the most common heart disease, the complexities of symptoms and the limitations of traditional testing can make it challenging for physicians to correctly identify the condition. The RoadMap analysis is designed to help improve CAD diagnosis by providing CT readers with a 2D visual that shows the location and severity of anatomic narrowings in the coronary arteries. It has been shown to provide accurate*, reproducible results and helps facilitate standardized and high-quality CT interpretation.2 The RoadMap analysis, alongside HeartFlow’s FFRCT, aligns with the recently updated AHA/ACC chest pain guidelines and enhances existing diagnostic workflows by guiding treatment decisions and improving patient outcomes.3 “As a leader in non-invasive diagnosis of CAD, HeartFlow is intimately familiar with the challenges associated with diagnosing heart disease,” said John Farquhar, Chief Executive Officer of HeartFlow. “The RoadMap analysis underscores our commitment to delivering products that meet the needs of physicians and ultimately helps deliver improved treatment plans for patients with suspected CAD – no matter how their disease may present itself.” “The RoadMap analysis has already been a valuable tool for our organization in helping us better pinpoint areas of stenosis and its severity,” said Michael Morris, M.D., a Diagnostic Radiology Specialist at Banner Health. “It helps our providers confidently determine the best next steps necessary to achieve improved patient care and outcomes.” The HeartFlow product suite now enables physicians to gain a more comprehensive understanding of a person’s CAD by assessing the coronary artery anatomy (RoadMap analysis), physiology (HeartFlow FFRCT), and plaque information (Plaque analysis) based on coronary computed tomography angiography (CCTA). When combined, they offer the most accurate approach to predicting the risk of a heart attack.4 *Accuracy data compared to measured QCA angiogram data. Data on file. For more information: www.heartflow.com References: 1 Centers for Disease Control and Prevention, National Center for Health Statistics. About Multiple Cause of Death, 1999–2020. CDC WONDER Online Database website. Atlanta, GA: Centers for Disease Control and Prevention; 2022. 2 Khasanova, et al. JCCT 2022. 3 Douglas, et al. The PRECISE Trial. Presented at AHA Scientific Sessions 2022. 4 Lee, et al. JACC Imaging 2019.
HeartFlow raises $215M to keep up with growing demand
The company is still riding the momentum of its technology being included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines.
HeartFlow Garners FDA Clearances for Two AI-Powered Assessment Tools with CCTA
Plaque Analysis and RoadMap Analysis, two artificial intelligence (AI)-enabled assessment products, may enhance clinical evaluation of coronary artery disease (CAD) on cardiac computed tomography angiography (CCTA).
VIDEO: HeartFlow FFR-CT sees increased interest after inclusion in the 2021 Chest Pain Guidelines
HeartFlow’s non-invasive cardiac computed tomography derived fractional flow reserve (FFR-CT) technology enables FFR values for the entire coronary tree of a patient using just a CT scan. This can show the significance of any coronary plaque lesions and if a patient needs to be sent to the cath lab for revascularization, or if they can be treated medically.
HeartFlow halts SPAC deal, citing 'current unfavorable market conditions'
In a move that may not bode well for the special purpose acquisition company deal’s recent dominance in medtech, HeartFlow’s plan to go public via reverse merger has been stalled. | In a move that may not bode well for the SPAC deal’s recent dominance in medtech, HeartFlow’s plan to go public has been halted.